Astel­las takes $435M+ write­down on Evren­zo, hear­ing loss can­di­date and T cell ther­a­py deal

Astel­las is book­ing hun­dreds of mil­lions of dol­lars in im­pair­ment loss­es this year af­ter end­ing a TCR T cell ther­a­py de­vel­op­ment deal, drop­ping a part­nered …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER